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Abstract
Motivation: Methods for analysis of GWAS summary statistics have encouraged data sharing and
democratized the analysis of different diseases. Ideal validation for such methods is application to
simulated data, where some ‘truth’ is known. As GWAS increase in size, so does the computational
complexity of such evaluations; standard practice repeatedly simulates and analyses genotype
data for all individuals in an example study.
Results: We have developed a novel method based on an alternative approach, directly simulating
GWAS summary data, without individual data as an intermediate step. We mathematically derive
the expected statistics for any set of causal variants and their effect sizes, conditional upon control
haplotype frequencies (available from public reference datasets). Simulation of GWAS summary
output can be conducted independently of sample size by simulating random variates about these
expected values. Across a range of scenarios, our method, produces very similar output to that
from simulating individual genotypes with a substantial gain in speed even for modest sample
sizes. Fast simulation of GWAS summary statistics will enable more complete and rapid evaluation
of summary statistic methods as well as opening new potential avenues of research in fine map-
ping and gene set enrichment analysis.
Availability and implementation: Our method is available under a GPL license as an R package
from http://github.com/chr1swallace/simGWAS.
Contact: cew54@cam.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The genome wide association study design is now more than a decade
old (Visscher et al., 2017), and the size of GWAS cohorts has contin-
ued to grow, from 1000 s to, now, 1 000 000 s of individuals. Given
the competing demands of open science and privacy concerns (P3G
Consortium et al., 2009), it has become standard to share data in the
form of summary statistics (allelic effect sizes and standard errors, or
simply P values) more readily than the full genotype data. A wealth of
methods have been developed to operate directly on the summary sta-
tistics, from fine mapping of genetic causal variants [e.g. PAINTOR
(Kichaev et al., 2014), CAVIARBF (Chen et al., 2015) and JAM
(Newcombe et al., 2016)] to (co-)heritability estimation (Bulik-
Sullivan et al., 2015) and integration of GWAS results from different
traits (Giambartolomei et al., 2014; Zhu et al., 2016). Summary data
methods are often derived through approximating a multivariate lin-
ear regression likelihood by incorporating information about correl-
ation structures (linkage disequilibrium, LD) from reference
populations. However, one must adopt a logistic regression approach
to correctly model risk on the log odds scale when analyzing GWAS
of binary traits (including case–control data). Summary statistic meth-
ods which have been originally derived for linear regression cannot do
this and the impact of the linearity assumption on their conclusions if
applied to case–control data has not been investigated in depth.
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As Biobank-sized datasets come to fruition, such summary statis-
tic methods are likely to become even more important, since, for
such large numbers of samples, operating on the complete genotype
data matrices for efforts such as Bayesian fine mapping of causal
variants is computationally prohibitive. Indeed, GWAS summary
statistics for multiple traits from UK-Biobank have already been
made freely available (Canela-Xandri et al., 2018). While Biobanks
tend to adopt a cohort design, meta-GWAS studies continue to over-
sample cases compared to controls, in order to increase the available
power, and are now exceeding 100 000 cases and controls in single
studies (Michailidou et al., 2017).
The gold standard for evaluating performance of summary statis-
tic methods is through analysis of simulated data, allowing inference
to be compared to a known ‘truth‘. A common method used by
GWAS simulators is to proceed by adding phenotypes to a sample of
genotype data that is either simulated or from a reference population
(‘forward simulation‘). This approach, in particular, can be used
very flexibly for generating multiple (quantitative) phenotypes, a de-
sign also common to Biobank datasets (Meyer and Birney, 2018).
However, this method does not lend itself to simulating case–control
data, since it simulates cases in proportion to what we would expect
to see in the reference population; typical GWAS designs recruit
cases disproportionally to their frequency in the population in order
to increase power. In order to forward simulate a GWAS cohort, we
would need to simulate until we had the required number of cases
and controls, discarding additional samples (typically a large num-
ber of controls as cases are normally a minority in the population).
This is computationally expensive, and wasteful.
Instead, when simulating case–control data, we typically simu-
late or sample genotype data conditional on a supposed distribution
of phenotypes. Simulation options in this case are more limited be-
cause the problem is mathematically harder. For single causal vari-
ant scenarios, resampling from a reference population conditional
on allele frequencies at a target variant may be used. For more com-
plicated causal models, involving multiple variants potentially in
LD, GWAsimulator (Li and Li, 2008), TriadSim (Shi et al., 2018) or
HAPGEN (Su et al., 2011) can very efficiently simulate haplotypes
for cases and controls in small genomic regions. In particular, by
incorporating mutations and recombinations, HAPGEN can simu-
late large populations with only a few hundred reference haplotypes.
However, the generation of GWAS summary statistics, e.g. using
SNPTEST (Marchini et al., 2007), requires analysis of the individual
level data which can be slow, particularly for logistic models which
require iterative optimization at each SNP.
The general approach of simulating both genotype and pheno-
type on an individual level cannot scale well for Biobank-scale or
large meta-GWAS situations, because of the number of individuals
required. It is also potentially wasteful—the individual level data are
not required when the goal is to evaluate methods that work on
summary statistics.
Here, we present an alternative approach, which simulates sum-
mary statistics directly, without needing to ever generate genotype
data. It scales as a function of the number of SNPs, but is constant
with regards to the number of samples, thus making it ideally designed
for simulation of summary statistics for large case–control studies.
2 Materials and methods
2.1 Overview of our approach
We first introduce the mathematical calculations which underpin
our method. Given a causal model specifying a region of interest,
which SNPs in the region are causal, their effects on disease in the
form of odds ratios, and reference data on allele and haplotype fre-
quencies in controls, we calculate the expected Z score from a
Cochran Armitage score test under an additive model at each SNP in
the region. [Cochran Armitage score tests have been used for GWAS
because of their computational simplicity, requiring no iterative
maximization procedure, and because they allow for additive, dom-
inant or recessive coding, although additive coding is the most com-
monly used (Sasieni, 1997)].
Simulated Z scores can then be derived by multivariate normal
simulation using standard software, with the variance-covariance
matrix calculated from correlations between the SNPs in the refer-
ence data. This suffices in the case where the summary statistic
methods to be used work upon Z scores alone. However, when log
odds ratios and their standard errors are required, we appeal to the
asymptotic similarity of score tests and Wald tests, and simulate
standard errors under the causal model. Together with simulated Z
scores, we can then back-calculate the log odds ratios as the product
of simulated Z scores and standard errors. An outline description of
our calculations follows; full details are given in the Supplementary
Material.
Let Yi 2 f0; 1g denote the indicator of disease status for the ith
of N individuals sampled according to case–control status (N1 cases,
Y i ¼ 1; N0 controls, Y i ¼ 0). Let n be the total number of SNPs. For
any SNP X, write GXi for its genotype coding 2 f0; 1; 2g at sample i.
Then, for the commonly used Cochran-Armitage score test, the Z-















where VX, VY denote varðXÞ; varðYÞ, respectively.
Write W ¼ ðW1; :::;WmÞT for the vector of causal SNPs and c ¼
ðc1; :::; cmÞT for their log odds ratios of effect. We assume that Yi
given GWi can be modelled as a binomial logistic regression:
PsamðYi ¼ 1jGWi ¼ wÞ ¼
ec0þc1w1þ:::þcmwm
1þ ec0þc1w1þ:::þcmwm
where PsamðÞ denotes that this is the probability within the
GWAS sample and c0 is chosen such that PsamðYi ¼ 1Þ ¼ N1N . The
conditioning is required because allele frequencies vary be-
tween cases and controls at causal variants and those in LD
with them, meaning the overall allele frequencies in our sample
differ from those in the population as a whole. By specifically
distinguishing between PsamðÞ and the more general PðÞ, we can
condition on having chosen N0 controls and N1 cases and thus
perform the conditional simulation needed for case–control
studies.
By conditioning upon the values of GW and Y, we obtain the











 ½2PðGXi ¼ 2 \GWi ¼ wÞ þ PðGXi ¼ 1 \GWi ¼ wÞ
(1)
The variance of UX is VXVY where VY ¼ N0N1NðN1Þ and VX is the
variance of GX. As VX is a variance, a natural model is an inverse
gamma distribution, VX  C1ða; bÞ. By similar conditioning upon
GW and Y, we show that the parameters of this distribution are














(the derivation of this and expressions for the first two moments of
VX are given in the Supplementary Material). This means we can ei-












so that, to a first order approximation,










Putting this together, we can now calculate the expected Z score,
ZE, across a set of SNPs, given a causal model and some phased ref-
erence data with which to calculate the probabilities in (Equation
1). Note that the computational complexity of this calculation is in-
dependent of both disease frequency and the number of samples
required.
For some applications, the expected Z Score may suffice.
However, note that the expected GWAS P value is not the P value
associated with the expected Z score. Instead, we must simulated
‘observed‘ GWAS results which vary randomly about ZE, with vari-
ance 1, such that the correlation between the Z score at two SNPs is
equal to the correlation between their genotypes (Burren et al.,
2014). It is hence computationally simple to simulate multiple real-
izations of GWAS Z scores as Z MVNðZE;RÞ, where R is a ma-
trix describing correlation between SNPs for the region, again
estimated from the reference panel.
To generate log odds ratios, c, and their standard errors, r, we
appeal to the asymptotic similarity of Wald tests from a logistic re-
gression model to the Cochran Armitage score test, and the result
that the variance of the score statistic UX is the inverse of the vari-
ance of the estimated c, under the null (McCullagh and Nelder,
1983). Thus, we simulate VX  Inverse Gammaða;bÞ with ða;bÞ





and calculate c ¼ rZ.
2.2 Simulations to validate summary statistics
We evaluated our proposed method by simulating summary statistics
in parallel using simGWAS (our method) and the same settings with
HAPGEN2þ SNPTEST2, using reference data from 1000 Genomes
Phase 3 (1000 Genomes Project Consortium et al., 2015) (AFR cohort,
600 subjects). Reference data was downloaded from https://
mathgen.stats.ox.ac.uk/impute/impute_v2.html#refer
ence. We compared distributions of summary statistics visually and
with Kolmogorov-Smirnov tests, as well as time to create the statistics
under different scenarios. Full code to run these simulations is available
from http://github.com/chr1swallace/simgwas-paper.
3 Results
3.1 Validation of simulated summary statistics
We visually confirmed that the calculated ZE appeared sensible for a se-
lection of one to four independent causal SNP models in a single region
(Supplementary Fig. S1). We next simulated data using our method or an
individual-based method (HAPGENþSNPTEST) for five scenarios
(Table 1) for a more detailed evaluation. Note in particular the difference
between scenarios 4 and 5. In scenario 4, two variants in weak LD each
have a log odds ratio of log ð1:2Þ ¼ 0:18 or log ð1=1:2Þ ¼ 0:18. In
this case, marginal estimates of odds ratios are close to these values, and
Z scores are highly significant. In scenario 5, the pair of odds ratios are
the same, but at strongly linked variants (r2 ¼ 0:8). This would be
expected to cause the effect of one to be ‘cancelled‘ by the other in the
marginal associations, so that estimates of log OR are attenuated towards
1 and significance is dramatically lower, as seen for both HAPGENþ
SNPTEST and simGWAS simulations (Supplementary Fig. S2).
Table 1. Five simulation scenarios considered for validation of
results
Scenario Description
1 Single common causal variant, weak effect
MAF ¼ 0.5; odds ratio ¼ 1.1
2 Single low frequency causal variant, strong effect
MAF ¼ 0.02; odds ratio ¼ 1.5
3 Three causal variants, unlinked
MAF ¼ 0.27, 0.37, 0.26; odds ratios 1.1, 1.2, 1.3
4 Two causal variants, weakly linked
r ¼ 0.15; MAF ¼ 0.39, 0.25; odds ratios 1.2 and 1/1.2
5 Two causal variants, strongly linked
r ¼ 0.8; MAF ¼ 0.1, 0.15; odds ratios 1.2 and 1/1.2
Fig. 1. Results from simGWAS (sG) are visually similar to those from
HAPGENþSNPTEST (HG). The figure shows 350 SNPs from around the
causal variants in the simulated region under scenario 4, with 5000 cases and
5000 controls. Points show the median log10(P value) for each SNP, and
ranges the IQR across 1000 simulations. Location of causal variants are
marked with dotted lines
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Visually, the Manhattan plots generated by the two methods were
similar (Fig. 1). However, we did notice that simGWAS displayed
greater variability than HapGenþSNPTEST at the SNPs with small-
est P values. Formal comparison of the distribution of statistics
showed that the mean log OR and mean Z score were statistically
indistinguishable between the two methods, but that simGWAS pro-
duced results with greater variability, resulting in some statistically
significant differences in Kolmogorov-Smirnov tests comparing the
two distributions (Supplementary Table S1).
To investigate this, we conducted forward simulations at the
causal variants only in each scenario, as a gold standard, and found
that results from simGWAS more closely matched those from this
gold standard than did those from HapGenþSNPTEST (Fig. 2,
Supplementary Table S1).
Finally, we compared simulation speed of each strategy as the
number of causal variants, the number of samples and the number
of replicates varied. For a region with 1000 SNPs using AFR data
from 1000 Genomes (600 samples), both methods were very fast
(<30 s) for the simplest scenario of 1000 cases and 1000 controls.
We found that both methods required slightly, but negligibly, more
time as the number of causal variants increased from one to six (Fig.
3a). As expected, HAPGENþSNPTEST scaled linearly with either
the number of replications (number of complete sets of data simu-
lated from the same scenarios) or sample size, whereas simGWAS
timings were independent of either factor (Fig. 3b and c). This
emphasizes the potential for fast simulation of summary statistics
for very large case–control datasets.
4 Discussion
Simulating GWAS summary statistics in the context of case–control
studies, for any required causal model and set of odds ratios, has
Fig. 2. QQ plots comparing distribution of log OR at causal SNPs across 1000 simulations with 5000 cases and 5000 controls. Each plot compares the distribution
of log OR generated by simGWAS (sG, x-axis) to that from HapGenþSNPTEST (HG) or forward simulation (F). Distributions were compared using Kolmogorov-
Smirnov, and P values are shown in the top-right of each subplot. The label of each plot gives the corresponding ‘scenario-snp’ pair—i.e. the label 3-1 refers to
scenario 3, first causal SNP
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several potential applications. Primarily, simulated GWAS results
have become the accepted gold standard for validating newly devel-
oped statistical models for the analysis of GWAS data. Our intent is
to enable the faster simulation of summary statistics compared to in-
dividual level data simulation, while at the same time using consid-
erably less disk space. Although the method focuses on region-level
simulation, it can be used to generate genomewide statistics if
required, by breaking the each chromosome into approximately in-
dependent blocks, according to recombination hotspots or break-
points derived from examining correlation between genotypes
(Berisa and Pickrell, 2016).
We note that our method depends on an assumption of additiv-
ity—across alleles at each SNP, and across causal SNPs in a region.
This additive model is used by the overwhelming majority of GWAS
analyses, by genetic risk score approaches and by LD regression
methods (Bulik-Sullivan et al., 2015; Dudbridge et al., 2018). Thus
it seemed the sensible place to start. However, examining how these
methods which assume additivity perform when the underlying
model is not additive is an interesting research question. A future
direction to extend our method could be to adapt it to simulate data
under any genetic model by expressing disease risk as a function of
genotypes at causal SNP haplotypes. While we have focused on
retrospective case–control designs as an obvious gap in the GWAS
simulation toolbox, our methodology could be relevant in the area
of extreme-sampling designs, where power is maximized for a fixed
cost by sampling individuals with extreme values of a quantitative
trait, for example in a study of blood pressure (Warren et al., 2017).
We could adapt our method to this design by expressing the distri-
bution of haplotype frequencies as a function of a quantitative trait.
In addition to supporting method development, simulation of
GWAS statistics is also used in tests aggregating information across
sets of SNPs, e.g. for pathway analysis. Pathway analysis can test ei-
ther the global null, of no association between any SNP and pheno-
type, or the competitive null, which assumes there are some truly
associated SNPs, but that these are randomly distributed amongst
the sets of SNPs considered (i.e. those near genes in or out of the
pathway under test, or those corresponding to presence or absence
of a feature of interest). The second seems more appropriate, be-
cause it acknowledges that enrichment tests are performed in the
context of genome-wide significant associations having been already
found. However, the second is also much harder to simulate.
A common technique for simulating under a competitive null
is permutation testing; the underlying dataset is maintained, and
labels are permuted to generate new datasets where traits are
still associated, but there is no possible correlation to the feature of
interest. However, doing this so as not to destroy the genomic
structure within the region, can require inventive generation of null
distributions, for example, by circularization and permutation of
genomic features to allow empirical null distributions to be calcu-
lated under a competitive null (Trynka et al., 2015). While these
are efficient, they can only be used for features that span shorter dis-
tances than LD—e.g. for chromatin mark enrichment but not genes
collected in pathways.
To allow more simple simulation techniques to be used,
pathway-based tests of the competitive null have been adapted to
have the same expected null distribution as tests of the global null.
This requires replacing P values for individual genes by their ranks
(Evangelou et al., 2012) which loses distributional information.
There is therefore potential to further develop pathway or en-
richment test methodology if the distribution of test statistics under
a competitive null hypothesis could be derived. Our method would
naturally allow simulation of GWAS summary data under a specific
hypothesis about the location and magnitude of genetic effects, in
order to generate empirical null distributions for tests of the com-
petitive null, preserving genomic structure even when analysis is per-
formed across multiple regions.
Finally, our method could be used to evaluate output of fine-
mapping applied to real data. Particularly in regions where the patterns
of LD between putative associated SNPs are complex, it can be hard to
dissect what the true causal variants are. Different fine mapping meth-
ods make different assumptions about the number and independence
of causal variants, which can produce conflicting results (Newcombe
et al., 2016; Wallace et al., 2015). By generating expected summary
statistics under alternative fine-mapped solutions, it may be possible to




Fig. 3. Time taken to perform simulations under simGWAS or HAPGEN2þ
SNPTEST2 strategies. simGWAS is denoted by triangles and
HAPGENþSNPTEST2 by circles. Each point represents the mean time for 50
independent runs of the software, with standard deviation about that mean
indicated by the vertical bars. (a) The effect of number of causal variants on
run time. 2000 cases, 2000 controls, single replication, causal variants varying
from 1 to 6. (b) The effect of number of replications on run time. 2000 cases,
2000 controls, 2 causal variants, number of replications varying from 1 to 100.
(c) The effect of sample size on run time. single replication, 3 causal variants,
number of cases and controls (each) varying from 1000 to 64 000
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Our method enables faster simulation of GWAS case–control
summary statistics compared to individual level data simulation, at
the same time using considerably less disk space. This should facili-
tate computationally simpler evaluation of existing and new sum-
mary GWAS methods and has the potential to underpin new
method development in other areas.
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